&w=3840&q=100)
Analysts cut LTIMindtree share price target after Q4 nos; details here
LTIMindtree shares today climbed 1 per cent in early deals to hit a high of ₹4,585 per share. They, however, gave up gains and hit a low of ₹4,450 per share in the intraday trade
LTIMindtree share price today: Factoring-in a weak March 2025 quarter, analysts have cut LTIMindtree share price target for the next one year. They, now, see up to 14.5 per cent upside in the information technology (IT) stock.
"While our financial year 2025-26 (FY26) estimates remain largely unchanged for LTIMindtree, we lower our FY27 earnings per share (EPS) estimate by around 5 per cent to account for the current macroeconomic headwinds. We now value LTIMindtree stock at 26x FY27E EPS (lower from 30x), leading to a revised target price of ₹5,150," said analysts at Motilal Oswal Financial Services on LTIM.
Meanwhile, on the bourses, LTIMindtree shares today climbed 1 per cent in early deals to hit a high of ₹4,585 per share. They, however, gave up gains and hit a low of ₹4,450 per share in the intraday trade. By comparison, the BSE Sensex index today is trading lower by 0.25 per cent at 10:55 AM.
LTIMindtree share: Should you buy, sell or hold?
Nuvama Institutional Equities on LTIMindtree share
Nuvama Institutional Equities has cut LTIMindtree share price target to ₹5,200 from ₹5,350 as the IT company saw a weak revenue growth momentum in H2FY25 amid macro uncertainties, delayed deal execution and client-specific challenges.
However, the brokerage maintained its 'Buy' rating on the stock as the management expects margins to improve from Q1FY26, driven by efficiency measures. Venu Lambu, the CEO-designate, highlighted key strategic initiatives such as sales transformation, revenue maximisation, and profitability enhancement by re-baselining of operational costs.
"LTIM is now in a unique position, wherein it is likely to deliver modest, but higher earnings growth than large-cap peers, while being available at a valuation similar to them. We continue to like the company, its strong delivery capabilities & clientele, and strong positioning in key verticals," it said.
Motilal Oswal says 'Buy' LTIMindtree stock
MOFSL maintained its 'Buy' rating on LTIM stock, supported by its capabilities in data engineering and ERP modernisation. The current stock price, analysts said, offers attractive valuation comfort.
Emkay Global Financial Services reviews LTIMindtree results
The brokerage has retained its 'Add' rating on the stock, but cut share target price ₹4,800, valuing the stock at 24x (earlier 25x) Mar-27E EPS. The brokerage liked LTIMindtree's healthy deal intake, BFSI, and Manufacturing momentum in Q4FY25. What it did not like was a miss on operating performance, and a weak cash conversion rate.
HDFC Securities sees 'gradual growth progression' in LTIMindtree
The key focus of the new CEO (designate) will be on sales transformation, which will involve simplifying the sales structure, strengthening leadership, reimagining value creation with partners and customers, and exploring new sales models for the AI economy.
The deal pipeline, the brokerage believes, remains robust, with healthy order inflows in Q4 and FY25, and sustained order book momentum likely to carry in FY26. It has cut LTIMindtree revenue and EPS estimates by 3-4 per cent, but maintained 'Add' on LTIM stock on a lowered share price target of ₹5,100.
LTIMindtree Q4 results 2025
LTIMindtree reported a net profit of ₹1,120 crore in Q4FY25, up 3.9 per cent quarter-on-quarter (Q-o-Q) and 2.5 per cent year-on-year (Y-o-Y). The IT company posted a revenue of $1.1 billion, down 0.6 per cent Q-o-Q in constant currency (CC). Further, reported Dollar revenue was down 0.7 per cent Q-o-Q, but up 5.8 per cent Y-o-Y.
Segment-wise, Manufacturing & Resources grew 2.3 per cent Q-o-Q and BFSI was up 1.2 per cent Q-o-Q. HiTech was down 1.5 per cent Q-o-Q, while Retail/Life Sciences declined 2.4 per cent/14 per cent Q-o-Q.
LTIMindtree noted an order inflows of $1.6 billion, down ~4.7 per cent Q-o-Q. FY25 order book stood at $6 billion.
About LTIMindtree
LTIMindtree is a merged entity, formed after the merger of LTI and Mindtree. The company posted a net profit of ₹4,600 crore for FY25, with a revenue of $4.5 billion. Its client portfolio includes more than 700 clients with overlapping limited to just 10-12 clients. LTIMindtree has 84,307 employees in more than 30 countries.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Economic Times
22 minutes ago
- Economic Times
Stock market update: Nifty Realty index falls 0.14%
NEW DELHI: The Nifty Realty index closed on a negative note on Monday. ADVERTISEMENT Shares of Anant Raj Ltd.(up 1.74 per cent), Phoenix Mills Ltd.(up 1.11 per cent) and Godrej Properties Ltd.(up 0.02 per cent) ended the day as top gainers in the pack. On the other hand, Brigade Enterprises Ltd.(down 1.98 per cent), Sobha Ltd.(down 1.29 per cent), Prestige Estates Projects Ltd.(down 0.36 per cent), Macrotech Developers Ltd.(down 0.29 per cent) and Oberoi Realty Ltd.(down 0.27 per cent) finished as the top losers of the day. The Nifty Realty index closed 0.14 per cent down at 1038.15. Benchmark NSE Nifty50 index ended up 100.16 points at 25103.2, while the BSE Sensex stood up 256.22 points at 82445.21. Among the 50 stocks in the Nifty index, 39 ended in the green, while 11 closed in the red. ADVERTISEMENT Shares of Vodafone Idea, JP Power, Reliance Power, Suzlon Energy and Capri Global were among the most traded shares on the NSE. Shares of Indef Manufacturing, Hybrid Financial Services, TVS Electronics, Sudarshan Chemical and MCX India hit their fresh 52-week highs in today's trade, while Shree Ram Proteins, Varanium Cloud, Techindia Nirman, BSL Ltd and United Drilling hit their fresh 52-week lows. ADVERTISEMENT (You can now subscribe to our ETMarkets WhatsApp channel)
&w=3840&q=100)

Business Standard
28 minutes ago
- Business Standard
Vijay Kedia portfolio stock soars 11%, hits new high; up 63% from March low
Share price of Sudarshan Chemical Industries today Shares of Sudarshan Chemical Industries hit a record high of ₹1,297.40, as they rallied 11 per cent on the BSE in Monday's intra-day trade amid heavy volumes. The stock price of this smallcap dyes and pigments company surpassed its previous high of ₹1,235 touched on October 14, 2024. It has bounced back 63 per cent from its March 2025 low price of ₹795.75 on the BSE. At 02:06 PM; Sudarshan Chemical Industries was quoting 8 per cent higher at ₹1,267.55, as compared to 0.32 per cent rise in the BSE Sensex. A combined 830,000 equity shares changed hands on the NSE and BSE. Vijay Kishanlal Kedia held over 1% stake in Sudarshan Chemical Industries Ace investor Vijay Kishanlal Kedia held 1 million equity shares or 1.27 per cent stake in Sudarshan Chemical Industries at the end of March 31, 2025 quarter, the shareholding pattern data shows. Besides Vijay Kedia, Akash Bhanshali (7.13 per cent), Vijaykumar Ramchandra Rathi (2.66 per cent stake), Rohit Kishor Rathi (2.62 per cent) and Lata Bhanshali (1.46 per cent) held more than 1 per cent stake in Sudarshan Chemical Industries, data shows. Check Ganga Bath Fittings IPO allotment status Reasons for delay in Sudarshan Chemical's Q4 results Sudarshan Chemical Industries entered into a definitive agreement on October 11, 2024, through its wholly-owned subsidiary Sudarshan Europe B.V., the Netherlands (SEBV), to acquire the Global Pigment Business Operations of the Heubach Group of Germany (Heubach Group) on a debt-free basis for a total consideration of EURO 127.5 million (approximately ₹1,180 crore). Pursuant to the acquisition, the company acquired and took control of 50 direct and step–down subsidiaries and 17 manufacturing sites from Heubach Group across various geographies across the globe. Prior to acquisition by the company, in April 2024, the German entities of the Heubach Group viz. a) Heubach Colorants Germany GmbH, (b) Heubach GmbH (c) Dr. Hans Heubach GmbH, and (iv) Heubach Group GmbH were declared insolvent and the Insolvency Administrator administered the process of sale of assets and business operations of German Entities in terms of provisions of the German Insolvency Law. The acquisition was funded through a mix of equity and debt. Accordingly, Sudharshan's Board of Directors approved a proposal for raising funds of ₹1,000 crore plus green shoe option up to 25 per cent by way of issuance of equity shares or any other eligible securities through permissible modes. On March 03, 2025, the company announced the completion of the acquisition of Global Pigment Business Operations of Heubach Group of Germany. Prior to this acquisition, the company had 8 direct and step-down subsidiaries. The company is required to submit audited financial results for FY 2024-25, including the newly acquired subsidiaries, by May 30, 2025. However, because of the insolvency impact, extensive financial reporting integration, complexities involved in business combination accounting, the company said it would not be able to meet the deadline. The company further said it shall declare its financial results for financial year ended March 31, 2025 post completion of the above-mentioned activities and the intimation about the same shall be provided to the Stock Exchanges in due course. CRISIL Ratings Rationale The acquisition will help Sudharshan emerge as a leading global pigment company with a presence across 19 countries, as well as 17 manufacturing facilities in 11 countries. The Heubach group is the second largest player in the global pigment sector and is estimated to have reported revenues of close to around EURO 800 million. However, the Heubach group faced financial challenges recently, due to headwinds from the Ukraine-Russia conflict leading to high energy prices, which was followed by weak demand scenario in key European markets. This impacted profitability and along with high debt levels led to the group filing for bankruptcy. Post-acquisition, Sudharshan's group revenues will witness a material increase with inclusion of Heubach group turnover and its market position in the pigments business will solidify. Revenue growth of the company's existing business is expected to continue however, it may moderate owing to looming geo-political headwinds. While the operating margin of existing business will sustain at current level of around 13 per cent, the consolidated operating margin is expected to reduce due to initial lower operating profitability of the Heubach Group, as well as post-acquisition spend on turnaround and re-optimsation of manufacturing operations. As a result, during initial period, the financial risk profile is expected to moderate to average levels, from earlier comfortable levels, CRSIL Ratings said in report dated April 19, 2025. During the nine months ended December 31, 2024, Sudharshan registered a profit after tax of ₹102 crore (₹54 crore in corresponding period of fiscal 2024) on net sales of ₹1,996 crore (₹1,775 crore). About Sudarshan Chemical Industries Sudarshan Chemical Industries is a globally renowned pigment player and the largest in India, manufacturing a wide range of organic and inorganic pigments and mica-based effect pigments. The company, which was established in 1951, remained focused on the domestic market till 2006. The joint venture with Dainippon Ink Corporation (DIC) was operational between 1990 and 2006; post which SCIL went global, establishing its footprint in North America Europe and other geographies. The company has two manufacturing facilities in Roha and Mahad (both in Maharashtra).


Economic Times
37 minutes ago
- Economic Times
Stock market update: Nifty Pharma index advances 0.66%
NEW DELHI: The Nifty Pharma index closed on a positive note on Monday. ADVERTISEMENT Shares of Laurus Labs Ltd.(up 3.95 per cent), Biocon Ltd.(up 2.46 per cent), Zydus Lifesciences Ltd.(up 1.41 per cent), Divi's Laboratories Ltd.(up 1.36 per cent) and Granules India Ltd.(up 1.26 per cent) ended the day as top gainers in the pack. On the other hand, J B Chemicals & Pharmaceuticals Ltd.(down 1.47 per cent), Lupin Ltd.(down 0.26 per cent), Dr. Reddy's Laboratories Ltd.(down 0.14 per cent), Ipca Laboratories Ltd.(down 0.12 per cent) and Aurobindo Pharma Ltd.(down 0.1 per cent) finished as the top losers of the day. The Nifty Pharma index closed 0.66 per cent up at 21826.8. Benchmark NSE Nifty50 index ended up 100.16 points at 25103.2, while the BSE Sensex stood up 256.22 points at 82445.21. Among the 50 stocks in the Nifty index, 39 ended in the green, while 11 closed in the red. ADVERTISEMENT Shares of Vodafone Idea, JP Power, Reliance Power, Suzlon Energy and Capri Global were among the most traded shares on the NSE. Shares of Indef Manufacturing, Hybrid Financial Services, TVS Electronics, Sudarshan Chemical and MCX India hit their fresh 52-week highs in today's trade, while Shree Ram Proteins, Varanium Cloud, Techindia Nirman, BSL Ltd and United Drilling hit their fresh 52-week lows. ADVERTISEMENT (You can now subscribe to our ETMarkets WhatsApp channel)